000272840 001__ 272840
000272840 005__ 20241028164615.0
000272840 0247_ $$2doi$$a10.1007/s00702-024-02817-8
000272840 0247_ $$2pmid$$apmid:39153024
000272840 0247_ $$2pmc$$apmc:PMC11489269
000272840 0247_ $$2ISSN$$a0375-9245
000272840 0247_ $$2ISSN$$a0022-3026
000272840 0247_ $$2ISSN$$a0300-9564
000272840 0247_ $$2ISSN$$a1435-1463
000272840 037__ $$aDZNE-2024-01258
000272840 041__ $$aEnglish
000272840 082__ $$a610
000272840 1001_ $$00000-0001-7680-2147$$aPötter-Nerger, Monika$$b0
000272840 245__ $$aThe akinetic crisis in Parkinson's disease - the upper end of a spectrum of subacute akinetic states.
000272840 260__ $$aWien [u.a.]$$bSpringer$$c2024
000272840 3367_ $$2DRIVER$$aarticle
000272840 3367_ $$2DataCite$$aOutput Types/Journal article
000272840 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1730125694_21847$$xReview Article
000272840 3367_ $$2BibTeX$$aARTICLE
000272840 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000272840 3367_ $$00$$2EndNote$$aJournal Article
000272840 520__ $$aThe akinetic crisis is defined as an acute, potentially life-threatening, levodopa-resistant, severe aggravation of rigidity, severe akinesia, associated with high fever, disturbance of consciousness, dysphagia and autonomic symptoms often due to disruption of dopaminergic medication or infections. The akinetic crisis is a relatively rare event, however subacute mild-moderate motor symptom deterioration in Parkinson´s disease (PD) patients is a frequent cause of hospitalization. In this review, we propose that the akinetic crisis is the upper end of a continuous spectrum of acute akinetic states depending on the degree of the progressive levodopa-resistance. Clinical symptomatology, risk factors, and instrumental diagnostics as the DAT-SPECT reflecting a biomarker of levodopa-resistance will be discussed to evaluate the spectrum of akinetic states. Pathophysiological considerations about the potential role of proinflammatory cytokines on the progressive levodopa-resistance will be discussed and therapeutical, consensus-based guidelines will be presented.
000272840 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000272840 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000272840 650_7 $$2Other$$aAkinetic crisis
000272840 650_7 $$2Other$$aCytokines
000272840 650_7 $$2Other$$aNeuroleptic malignant-like syndrome
000272840 650_7 $$2Other$$aParkinsonism-hyperpyrexia syndrome
000272840 650_7 $$2Other$$aParkinson’s disease
000272840 650_7 $$2Other$$aRisk factors
000272840 650_7 $$2Other$$aSpectrum acute akinetic states
000272840 650_7 $$2Other$$aTherapy
000272840 650_7 $$2NLM Chemicals$$aAntiparkinson Agents
000272840 650_7 $$046627O600J$$2NLM Chemicals$$aLevodopa
000272840 650_2 $$2MeSH$$aHumans
000272840 650_2 $$2MeSH$$aParkinson Disease: drug therapy
000272840 650_2 $$2MeSH$$aParkinson Disease: complications
000272840 650_2 $$2MeSH$$aParkinson Disease: physiopathology
000272840 650_2 $$2MeSH$$aParkinson Disease: diagnosis
000272840 650_2 $$2MeSH$$aAntiparkinson Agents: therapeutic use
000272840 650_2 $$2MeSH$$aLevodopa
000272840 650_2 $$2MeSH$$aDrug Resistance
000272840 7001_ $$aSchrader, Christoph$$b1
000272840 7001_ $$aJost, Wolfgang H$$b2
000272840 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter$$b3$$eLast author$$udzne
000272840 773__ $$0PERI:(DE-600)1481655-6$$a10.1007/s00702-024-02817-8$$gVol. 131, no. 10, p. 1199 - 1207$$n10$$p1199 - 1207$$tJournal of neural transmission$$v131$$x0375-9245$$y2024
000272840 8564_ $$uhttps://pub.dzne.de/record/272840/files/DZNE-2024-01258.pdf$$yOpenAccess
000272840 8564_ $$uhttps://pub.dzne.de/record/272840/files/DZNE-2024-01258.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000272840 909CO $$ooai:pub.dzne.de:272840$$popenaire$$popen_access$$pVDB$$pdriver$$pdnbdelivery
000272840 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000272840 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000272840 9141_ $$y2024
000272840 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000272840 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-21
000272840 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000272840 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-21
000272840 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-21
000272840 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURAL TRANSM : 2022$$d2023-10-21
000272840 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000272840 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-21
000272840 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2023-10-21$$wger
000272840 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000272840 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-10-21
000272840 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000272840 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-21
000272840 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000272840 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000272840 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000272840 9201_ $$0I:(DE-2719)1110002$$kAG Höglinger$$lTranslational Neurodegeneration$$x0
000272840 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x1
000272840 980__ $$ajournal
000272840 980__ $$aVDB
000272840 980__ $$aUNRESTRICTED
000272840 980__ $$aI:(DE-2719)1110002
000272840 980__ $$aI:(DE-2719)1111015
000272840 9801_ $$aFullTexts